The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: Do you want to introduce who's on stage with you?
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: So I just want to remind everybody that there are three ways to ask a question, right? There's the old way, raise your hand, and I will
call on you. You can submit a question in the e-mail portal, and -- or you could just e-mail me. But maybe I'll start. You guys obviously
beat consensus in 4Q for ELEVIDYS pretty handily, actually. But I'm just wondering now, with that beat, how do you think about the
push-pull levers for the ELEVIDYS guidance?
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: We have a -- yes, a question in the audience. Great, raise your hand.
Unidentified Participant
A question on the redosing technology in the two- and three-year follow-up data, what your expectation for the need for redosing.
I turned over the [transcript today].
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 13, 2025 / 5:00PM, SRPT.OQ - Sarepta Therapeutics Inc at JPMorgan Healthcare Conference
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: We have a question in the portal, which is related to the $30 billion in cumulative revenue by 2030. What contribution are you
expecting from limb-girdle and other pipeline programs? Is this assuming success or risk adjusted?
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: Questions from the audience? Maybe one for me. So what are you seeing in the field in terms of how physicians are prioritizing
patients on ELEVIDYS therapy, because you've got a pretty wide label, right?
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: Questions from the audience? What are you seeing on sort of reimbursement timelines when -- once a patient has been selected
for therapy and getting through that process? You've talked about the 25 people too.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 13, 2025 / 5:00PM, SRPT.OQ - Sarepta Therapeutics Inc at JPMorgan Healthcare Conference
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: Maybe a final question for me. Doug, I believe that your contract at Sarepta may be coming to an end shortly. You've been in the
industry a long time. You've had a really good career. You trailblazed the ELEVIDYS approval. So what is -- what's next for you?
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: Well, you did spill the water on your shoes.
| 
